Short Report
Hero Background

Cut through the noise.
Trade on the signal.

A weekly synthesis of institutional-grade financial reports and market mechanics.

No spam. Unsubscribe anytime.

Filters

Companies

Tickers

Authors

Latest Reports

Company: Two Natural Capital Author: Two Natural Capital

Two Natural Capital: Covalent Drugs Cracked RAS After 40 Years of Failure — Here Is the Metric Investors Are Missing When Evaluating Them

Binding affinity alone is the wrong number for covalent drugs — kinact and kinact/KI are what matter, and a company that emphasizes Ki over those metrics may be showing you a misleading picture of its compound's quality.

Apr 30, 2026 6 min read
Ticker: TERN Company: Terns Pharmaceuticals

Merck's $5.7B Terns Bet Rests on 38 Patients: Does TERN-701 Justify the Price Over Asciminib?

Two Natural Capital argues Merck's bid isn't obviously cheap -- the merger process showed two bidders wouldn't top Terns' market price and a third walked away after seeing updated trial data showing lower MMR rates than previously disclosed

Apr 8, 2026 6 min read
Author: Two Natural Capital

Antibodies, Antibody Fragments, and Peptides: Targeting Muscular Diseases with RNA

RNA therapeutics targeting muscular diseases face unresolved delivery and nuclear access challenges that companies may be understating, with PepGen's 53.7% splicing correction dwarfing Avidity's 16% and Dyne's 27% — raising questions about measurement consistency or overstated claims

Dec 19, 2025 6 min read
Author: Two Natural Capital Ticker: CASY

Casey’s General Stores: A Dollar General Approach to Gas Stations $casy

Casey's General Stores expansion strategy challenges rural market dominance, with aggressive acquisitions, pizza market growth, and potential competitive risks in emerging markets, analyzing stock performance and EV impact

May 7, 2025 3 min read
Author: Two Natural Capital Ticker: TXG

In Situ Sequencing: 10x Genomics, NanoString, and Vizgen $txg $brkr

10x Genomics Xenium leads spatial genomics with superior FFPE tissue analysis, outperforming NanoString and Vizgen in transcript capture. Legal battles reshape in situ sequencing market, revealing critical platform performance differences

Apr 25, 2025 3 min read
Author: Two Natural Capital Ticker: SRPT

Sarepta Therapeutics: From Exon-Skipping to Gene Therapy

Sarepta Therapeutics' ELEVIDYS gene therapy for Duchenne muscular dystrophy faces critical challenges: controversial FDA approval, $3.2M price tag, limited efficacy, and potential competitive threats from emerging genetic treatments

Dec 12, 2024 3 min read

The Signal. No Noise.

Join 50,000+ investors receiving our weekly synthesis.